Anupam Rasayan India Limited has announced its financial results for the second quarter (Q2) and the first half (H1) of FY27. The company reported strong consolidated revenues and EBITDA growth, driven by operational highlights and strategic acquisitions. Key developments include the acquisition of Bliss GVS Pharma and Jayhawk Fine Chemicals, aimed at expanding its pharmaceutical and specialty chemical offerings and strengthening its global presence.
Anupam Rasayan India Announces Q2 & H1 FY27 Financial Performance
Anupam Rasayan India Limited has officially published its financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2026-2027. The company has showcased significant growth across key financial metrics, underscoring its robust performance and strategic initiatives.
Quarterly Financial Highlights (Q2 FY27)
- Consolidated Total Revenue: ₹821 Crore, with a 23% Quarter-on-Quarter (Q-o-Q) growth.
- Consolidated EBITDA: ₹202 Crore, reflecting a 16% Q-o-Q growth.
- Consolidated Profit After Tax: ₹65 Crore, showing a substantial 27% Q-o-Q increase.
- Standalone Total Revenue: ₹413 Crore, up 23% Q-o-Q.
- Standalone EBITDA: ₹141 Crore, with a 22% Q-o-Q growth.
- Standalone Profit After Tax: ₹46 Crore, marking a significant 43% Q-o-Q rise.
Half-Yearly Financial Highlights (H1 FY27)
- Consolidated Total Revenue: ₹1,489 Crore, an increase of 21% Year-on-Year (Y-o-Y).
- Consolidated EBITDA: ₹377 Crore, up 38% Y-o-Y.
- Consolidated Profit After Tax: ₹116 Crore, a 10% Y-o-Y growth.
- Standalone Total Revenue: ₹748 Crore, with a 2% Y-o-Y growth (excluding one-off sale).
- Standalone EBITDA: ₹257 Crore, a 19% Y-o-Y increase.
- Standalone Profit After Tax: ₹78 Crore, up 9% Y-o-Y.
Key Operational Highlights for H1 FY27
- Achieved the highest-ever quarterly consolidated revenue of ₹812 Cr in Q2 FY27, with a 10% YoY growth.
- Consolidated EBITDA grew by 41% YoY to ₹202 Cr, with margins improving to 25%.
- Generated operating cash flow of ₹328 crore as of September 2026.
Strategic Acquisitions and Developments
- Bliss GVS Acquisition: Completed the acquisition of a 50.07% controlling stake, enhancing its presence in the pharmaceutical sector and its finished dosage formulations capabilities.
- Long-Term Supply Contract: Signed a six-year contract with a leading US-based specialty metal manufacturer, marking an entry into the geological resources sector.
- Strategic Investment: Strengthened investment in Tanfac Industries through a preferential equity issue.
- ESG Ratings: Received strong Crisil ESG ratings, an improvement from the previous year.
Managing Director’s Message
The Managing Director, Mr. Anand S Desai, highlighted H1 FY27 as a period of steady progress, strategic expansion, and portfolio strengthening. He emphasized the company’s focus on building a globally integrated specialty chemicals platform and leveraging new acquisitions to drive growth and create stakeholder value.
Source: BSE
